Post on 30-Dec-2015
description
Jain RK et al. (2006) Lessons from phase III clinical trials on anti-VEGF therapy for cancerNat Clin Pract Oncol 3: 24–40 doi:10.1038/ncponc0403
Table 3 Completed Phase III trials for multi-targeted agents with VEGF receptor 2 kinase as one of their targets